Cook G J, Fogelman I
Department of Nuclear Medicine, Royal Marsden Hospital, Sutton, Surrey, UK.
Q J Nucl Med. 2001 Mar;45(1):47-52.
The use of positron emission tomography (PET) in clinical oncology continues to increase and although there is now a large literature on the use of PET with various tracers in a wide variety of cancers, there has previously been relatively little use specifically in the evaluation of skeletal metastases. However, a number of reports on PET in this area of oncology are now becoming available. The potential advantages of PET over conventional nuclear medicine techniques, including improved spatial resolution, absolute quantitation and the acquisition of tomographic studies as a routine, are also of potential benefit in this area. The bone agent, 18F-fluoride and the tumour agent 18F-fluorodeoxyglucose, have been used to evaluate both benign and malignant skeletal disorders qualitatively and quantitatively and the current knowledge with respect to the skeleton in cancer patients is summarised in this article.
正电子发射断层扫描（PET）在临床肿瘤学中的应用持续增加。尽管目前已有大量关于在各种癌症中使用PET及各种示踪剂的文献，但此前在骨骼转移瘤评估方面的具体应用相对较少。然而，现在有关肿瘤学这一领域中PET的一些报告开始出现。PET相对于传统核医学技术的潜在优势，包括提高空间分辨率、绝对定量以及常规获取断层扫描研究结果，在这一领域也具有潜在益处。骨显像剂18F - 氟化物和肿瘤显像剂18F - 氟脱氧葡萄糖已被用于定性和定量评估良性和恶性骨骼疾病，本文总结了目前关于癌症患者骨骼方面的知识。
